Clinical Disclaimer
This protocol is for research and educational purposes only. Lyme disease and Babesia require physician-supervised care by an experienced clinician, ideally an ILADS-trained physician. Do not self-diagnose or self-treat. This protocol is proposed as adjunctive to medical care, not as a replacement. Botanical anti-microbials described herein are not FDA-approved treatments for Lyme disease or Babesia. All supplements should be initiated with physician awareness. Not FDA approved.
Chronic Lyme disease and its frequent co-infection Babesia present one of the most challenging clinical problems in modern medicine: a multi-system illness caused by a pathogen that has evolved sophisticated strategies to evade immune surveillance, resist conventional antibiotics, and deplete the host's biological resources. This paper presents the Christos™ Lyme & Babesia Reversal Protocol — a four-tier, 6–12 month coherence-based framework that simultaneously addresses both the pathogen (through evidence-based botanical anti-microbials) and the host (through comprehensive mineral restoration, mitochondrial repair, immune regulation, and field coherence). The scientific foundation draws on the University of New Haven Lyme Research Group (Theophilus et al., 2015: stevia whole-leaf extract reduced Borrelia biofilm by 40%), the Johns Hopkins botanical Lyme study (Feng et al., 2020: Cryptolepis sanguinolenta showed highest activity against all Borrelia forms), and published data on mineral depletion, oxidative stress, and mitochondrial dysfunction in chronic Lyme. Two specialized frequency-imprinted healing fluids are introduced (formulations under NDA): LymeFlux (anti-Borrelia botanical matrix) and BabesiaClear (anti-Babesia and immune restoration). The core thesis: the host's coherence state is the primary determinant of whether Borrelia becomes chronic or is cleared. Restoring coherence is the master intervention.
Part I. Understanding Chronic Lyme — The Coherence Perspective
The Scope of the Problem
Lyme disease is caused by Borrelia burgdorferi, transmitted by the Ixodes tick. The CDC estimates 476,000 new Lyme disease cases annually in the United States alone. Approximately 10–20% of treated patients develop Post-Treatment Lyme Disease Syndrome (PTLDS) — persistent symptoms lasting months to years after standard antibiotic courses. Three NIH-funded double-blind RCTs of extended antibiotic therapy (Klempner et al., 2001; Krupp et al., 2003; Fallon et al., 2008) found minimal benefit from additional antibiotics, supporting the conclusion that antibiotic-resistant persistence mechanisms, not antibiotic-susceptible spirochetes, drive PTLDS.
Babesia — The Underdiagnosed Co-Infection
Babesia microti and Babesia divergens are intraerythrocytic parasites transmitted by the same Ixodes tick. Approximately 20–40% of Lyme disease patients have Babesia co-infection (Krause et al., 2002). Babesia causes a malaria-like illness — fever, sweats, fatigue, hemolytic anemia — and profoundly worsens Lyme outcomes. Critically, standard Lyme antibiotics have no activity against Babesia, making accurate diagnosis and species-specific treatment essential.
Part II. The Five Borrelia Survival Mechanisms
| Mechanism | How It Works | Why Antibiotics Fail | Coherence Response |
|---|---|---|---|
| Biofilm formation | Borrelia aggregates into extracellular polymeric substance matrix | Standard antibiotics penetrate poorly; cells inside biofilm exhibit 1,000× antibiotic tolerance | Biofilm-disrupting botanicals (stevia, NAC, garlic) + coherence field disruption of biofilm architecture |
| Cyst/round body conversion | Morphs into dormant spherical cyst form | Cysts are metabolically inactive; antibiotics that target active replication fail | Pulse dosing; botanicals with cyst activity (Cryptolepis); coherence restoration changes host environment favoring clearance |
| Intracellular refuge | Invades host cells (neurons, macrophages, endothelium) | Antibiotics with poor CNS/intracellular penetration cannot reach | Fat-soluble botanicals with intracellular penetration; photobiomodulation to affected tissues |
| Mineral sequestration | Actively sequesters zinc, magnesium, selenium from host | Host immune function deteriorates; energy production fails | Mineral restoration as non-negotiable foundation; re-supplying sequestered minerals restores host coherence |
| Immune evasion | Evades innate immunity; suppresses Th1 cellular immune response | Immune system cannot mount effective clearance response | Immune coherence restoration; Th1 reactivation through botanicals and vitamin D; reishi and astragalus |
Oxidative and Mitochondrial Disruption Data
| Parameter | Status in Chronic Lyme | Source |
|---|---|---|
| 8-OHdG (DNA oxidative damage) | 2–3× elevated vs controls | Pancewicz et al. (2001), J Neurol Sci |
| Glutathione | ~50% reduced | Nicolson et al. (2002) |
| CoQ10 | Depleted | Horowitz (2017) |
| ATP production | Reduced | Nicolson et al. (2002); Myhill et al. (2009) |
| Zinc | Depleted (actively sequestered by Borrelia) | Donta (2002); Horowitz (2017) |
| Magnesium | Depleted | Nicolson et al. (2002) |
| Th1 cytokines (IFN-γ) | Suppressed | Widhe et al. (2004) |
| IL-6, TNF-α, IL-1β | Elevated | Sjöwall et al. (2011) |
Part III. The Coherence Model of Lyme Disease
| Phase | High Coherence Host (C > 0.6) | Low Coherence Host (C < 0.5) |
|---|---|---|
| Acute infection | Innate immune response rapid; antibiotics work efficiently | Innate immune response delayed; biofilm formation begins; antibiotic penetration impaired |
| Treatment course | Spirochetes cleared; minimal cyst conversion; full recovery | Cyst forms survive; biofilm persists; minerals further depleted |
| Post-treatment | Full resolution; no PTLDS | Persistent symptoms; ongoing biological dysregulation; PTLDS |
The Vicious Cycle
Low host coherence allows Borrelia persistence, which actively drives coherence further downward through mineral sequestration, oxidative stress, mitochondrial damage, and immune dysregulation. Breaking this cycle requires simultaneously addressing both the pathogen (biofilm disruption, Babesia elimination) and the host (mineral repletion, mitochondrial repair, immune regulation). Neither alone is sufficient.
Part IV. Botanical Anti-Borrelia Evidence
The Theophilus et al. (2015) Stevia Study — University of New Haven
The most striking botanical finding in the Lyme research literature (European Journal of Microbiology and Immunology). Stevia rebaudiana whole leaf extract was systematically evaluated against all known morphological forms of Borrelia burgdorferi in vitro — spirochetes, persisters, and attached biofilms.
| Form | Stevia Result | Antibiotic Comparison |
|---|---|---|
| Log-phase spirochetes | ~94% reduction (p≤0.01) | Doxycycline: comparable activity |
| Persister (stationary phase) | ~84% reduction (p≤0.01) | Antibiotics: limited activity against persisters |
| Biofilm on plastic | ~40% reduction (p≤0.01) | Antibiotics INCREASED biofilm mass vs untreated controls |
| Biofilm on collagen | ~34% reduction (p≤0.01) | Antibiotics INCREASED biofilm mass vs untreated controls |
Critical Finding
Individual antibiotics actually increased Borrelia biofilm mass. Stevia whole leaf extract reduced it by 40%. This is published data from the University of New Haven Lyme Disease Research Group. Whole-leaf preparation is essential — purified stevioside showed minimal activity.
The Feng et al. (2020) Johns Hopkins Botanical Study
| Agent | Activity (Growing) | Activity (Non-Growing/Biofilm) | Notes |
|---|---|---|---|
| Cryptolepis sanguinolenta | High | High — among top performers | Superior to most tested agents across all forms |
| Juglans nigra (Black walnut hull) | High | High | Strong activity; well-tolerated |
| Polygonum cuspidatum (Japanese knotweed) | Moderate-High | Moderate | Contains resveratrol; anti-inflammatory benefit |
| Artemisia annua (Sweet wormwood) | Moderate | Moderate | Also active against Babesia |
| Uncaria tomentosa (Cat's claw) | Moderate | Moderate | Immune-modulating properties |
| Doxycycline (comparator) | High | Low — poor biofilm activity | Standard of care; fails against non-growing forms |
The Hopkins authors called for clinical evaluation of these botanical agents. The Christos™ Lyme protocol builds directly on their findings, combining the top performers from both studies with host coherence restoration.
Part V. The Four-Tier Protocol
Tier 1 — Foundation: Mineral Restoration and Cellular Repair (Non-Negotiable)
| Supplement | Dose | Form | Evidence |
|---|---|---|---|
| Zinc | 50 mg/day | Picolinate | Donta (2002); Horowitz (2017) — depleted in chronic Lyme; immune function restoration |
| Copper | 2 mg/day (concurrent with zinc) | Gluconate | Prevents zinc-induced copper depletion; ratio maintenance |
| Magnesium | 600–800 mg/day | Glycinate (anxiety/sleep) or Malate (fatigue) | Nicolson et al. (2002); Horowitz (2017) — depleted; ATP synthesis critical |
| Selenium | 200 mcg/day | Selenomethionine | Donta (2002) — depleted by oxidative stress; glutathione production |
| CoQ10 (ubiquinol) | 200–400 mg/day | Ubiquinol (best absorbed) | Nicolson et al. (2002); Horowitz (2017) — mitochondrial restoration |
| D-Ribose | 5 g 3×/day with meals | Standard | Teitelbaum et al. (2006) RCT: direct ATP substrate; fatigue improvement |
| Glutathione (liposomal) | 500 mg/day | Liposomal | Nicolson et al. (2002) — depleted; primary antioxidant repletion |
| N-Acetyl Cysteine (NAC) | 600–1,200 mg 2×/day | Standard | Glutathione precursor; also disrupts biofilm extracellular matrix |
| Alpha-lipoic acid | 600 mg/day | Standard | Packer (1998); Nicolson (2002) — mitochondrial antioxidant; glutathione regeneration |
| Vitamin D3 | 5,000–10,000 IU/day | D3 | Immune coherence; Th1 restoration; 25-OH-D goal 60–80 ng/mL |
Tier 2 — Biofilm Disruption
| Agent | Dose | Evidence | Notes |
|---|---|---|---|
| Stevia whole leaf extract | 500 mg 3×/day | Theophilus et al. (2015): 40% biofilm reduction; 94% spirochete reduction | Must be whole leaf, not purified stevioside. Nutramedix brand used in study. |
| Garlic extract (allicin-standardized) | 600–1,200 mg/day | Feng et al. (2020): active against Borrelia forms | High-allicin content essential for anti-Borrelia activity |
| NAC | 600–1,200 mg 2×/day (already in Tier 1) | Disrupts biofilm extracellular polysaccharide matrix | Doubles as antioxidant and glutathione precursor |
| Lumbrokinase | 20 mg/day on empty stomach | Enzymatic fibrin dissolution; fibrin is scaffolding of Borrelia biofilm | Most potent systemic fibrinolytic enzyme for biofilm disruption |
Tier 3 — Botanical Anti-Microbials (Based on Feng et al. 2020 Hopkins Data)
| Agent | Dose | Activity Profile | Source |
|---|---|---|---|
| Cryptolepis sanguinolenta | 1 tsp tincture 3×/day | Highest activity against all Borrelia forms including biofilm | Feng et al. (2020) Johns Hopkins — top performer |
| Juglans nigra (Black walnut) | 500 mg 3×/day (hull extract) | High activity against growing and non-growing forms | Feng et al. (2020) — strong across all Borrelia morphologies |
| Polygonum cuspidatum (Japanese knotweed) | 500 mg 2×/day | Moderate-High; contains resveratrol (anti-inflammatory bonus) | Feng et al. (2020); also used in Buhner Lyme protocol |
| Artemisia annua | 500 mg 2×/day | Active against Borrelia; also effective against Babesia (critical for co-infection) | Feng et al. (2020); artemisinin anti-Babesia mechanism |
| Uncaria tomentosa (Cat's claw) | 500 mg 2×/day | Moderate activity; immune-modulating properties support host coherence | Feng et al. (2020); Buhner protocol component |
Tier 4 — Lifestyle (Non-Negotiable Foundation)
Sleep 8–9 hours minimum (critical for immune restoration and glymphatic clearance of neurotoxins). Coherence breathing 0.1 Hz daily (10–20 min — restores HRV, activates vagal anti-inflammatory reflex, supports lymphatic flow). Remove: alcohol, sugar, refined carbohydrates, gluten (each drives inflammation and impairs immune coherence). Light exercise maintained (walking, gentle yoga) — do not push through post-exertional malaise. EMF reduction in sleeping environment (Borrelia shown sensitive to electromagnetic environments; dirty electricity may support persistence).
Part VI. The Babesia Protocol
Babesia requires distinct treatment from Borrelia. Failure to treat co-infection is a primary reason for treatment failure in chronic Lyme. Standard FDA-approved treatment: atovaquone-proguanil + azithromycin (immunocompetent adults); exchange transfusion (severe cases). These remain the primary treatment and should not be bypassed.
| Intervention | Dose | Mechanism | Evidence |
|---|---|---|---|
| Artemisinin / Artemisia annua | 200 mg 2×/day (artemisinin extract) | Sesquiterpene lactone with documented anti-Babesia activity; same mechanism as malaria activity | Krause et al. (2000); Weiss (2002) case series; Tu Youyou Nobel Prize 2015 |
| Cryptolepis sanguinolenta | 1 tsp tincture 3×/day (same as Lyme tier) | Anti-protozoal activity; used in African traditional medicine for malaria-like illness | Feng et al. (2020) documented anti-Babesia properties |
| Iron support (if hemolytic anemia) | 15–30 mg elemental iron with vitamin C | Babesia causes hemolytic anemia through RBC destruction; iron repletion essential | Monitor CBC and ferritin; replete under physician guidance |
| Reishi mushroom | 1,000–2,000 mg/day | Immune modulation; Th1 activation; NK cell enhancement | Multiple studies on immune-modulating polysaccharides; critical for anti-parasitic immune response |
Babesia Warning
Babesia can cause life-threatening illness in immunocompromised patients, asplenic patients, and the elderly. Any patient with suspected Babesia requires medical evaluation and appropriate testing (thick blood smear, PCR, serology). Do not rely on botanical protocols alone for active Babesia infection. Conventional treatment with atovaquone + azithromycin is the standard of care and should be the primary treatment.
Part VII. The Healing Fluid System
Two specialized healing fluids are formulated for the Lyme & Babesia protocol, both on the Christos™ UHF structured deuterium-depleted water base with Solfeggio frequency imprinting:
| Fluid | Target | Primary Function | Key Botanical Mechanisms | Imprint Frequencies |
|---|---|---|---|---|
| LymeFlux | Anti-Borrelia; host coherence | Deliver concentrated biofilm-disrupting and anti-spirochete botanical matrix; support mineral repletion through fluid medium; restore cellular energy infrastructure | Cryptolepis (anti-Borrelia); stevia whole leaf (biofilm disruption); Japanese knotweed (anti-inflammatory + anti-Borrelia); NAC (biofilm + glutathione) | 396 Hz (liberation) + 528 Hz (cellular repair) |
| BabesiaClear | Anti-Babesia; immune restoration; red blood cell support | Deliver concentrated artemisinin-containing botanical matrix; support RBC integrity during hemolytic phase; activate NK cells and Th1 immunity critical for anti-parasitic response | Artemisia annua (artemisinin anti-Babesia); reishi (NK cell activation); cat's claw (Th1 support); iron + B12 (RBC support) | 285 Hz (cellular repair) + 396 Hz |
Protected IP — LymeFlux and BabesiaClear — Complete Formulation Specifications and Manufacturing Protocols
Complete formulation specifications, ingredient quantities, and device engineering specifications are proprietary.
Full Specifications Available Under Signed NDA ↗Part VIII. Device and Chamber Protocols
LymeResonator — Wearable Device
A wearable phi-ratio crystalline device designed for placement over the primary lymphatic drainage nodes (cervical, axillary, inguinal) delivering continuous 285 Hz and 528 Hz crystalline field entrainment. Purpose: support lymphatic coherence; enhance immune surveillance in lymphatic tissue; complement oral botanical anti-microbial protocol with continuous field delivery.
Protected IP — LymeResonator — Complete Device Engineering Specifications
Complete formulation specifications, ingredient quantities, and device engineering specifications are proprietary.
Full Specifications Available Under Signed NDA ↗Coherence Chamber — Lyme Protocol (75 Minutes)
| Phase | Duration | Modalities | Target | Frequencies |
|---|---|---|---|---|
| Phase 1: Detox & Lymphatic | 20 min | PEMF 7.83 Hz + structured water immersion (mineral-rich, mildly hyperthermic 100–102°F) + 396 Hz acoustics | Lymphatic activation; toxin mobilization; herxheimer mitigation | 7.83 Hz + 396 Hz |
| Phase 2: Anti-Microbial Field | 20 min | PEMF 528 Hz + red light 660 nm (immune tissue activation) + 528 Hz acoustics | Direct field intervention targeting Borrelia biofilm coherence disruption | 528 Hz (cellular repair frequency) |
| Phase 3: Mitochondrial Restore | 15 min | NIR 850 nm full body + 285 Hz acoustics + MitoFlux (via bath) | ATP production restoration; mitochondrial membrane potential | 285 Hz |
| Phase 4: Immune Integration | 20 min | 7.83 Hz PEMF + 639 Hz acoustics + coherent breathing (0.1 Hz) | Immune regulation; Th1 rebalancing; autonomic coherence | 639 Hz + 7.83 Hz |
Protected IP — Chamber Session Technical Specifications — PEMF Parameters, PBM Settings, Water Protocol
Complete formulation specifications, ingredient quantities, and device engineering specifications are proprietary.
Full Specifications Available Under Signed NDA ↗Part IX. Monitoring and Outcomes
| Parameter | Frequency | Target | Significance |
|---|---|---|---|
| Symptom tracking (MSAS, BLISS) | Weekly self-report | Progressive improvement; Herxheimer reactions document pathogen load | Primary patient-reported outcome |
| CD57 NK cells | Every 3 months | Rising trend toward normal range (>60 cells/μL) | CD57 is the primary immune biomarker for chronic Lyme; rises as Borrelia load decreases |
| Inflammatory panel (hs-CRP, IL-6) | Monthly (first 3 months); then quarterly | hs-CRP <1 mg/L; cytokine normalization | Tracks resolution of systemic inflammation; indicates host coherence restoration |
| Mineral panel (RBC-based) | Baseline; 3 months; 6 months | Cu/Zn approaching 0.8–1.2; Mg, Se normalized | Confirms mineral restoration; guides dose adjustment |
| HRV (SDNN) | Weekly home; monthly clinical | Progressive increase; SDNN >60 ms by month 6 | Global coherence proxy; most predictive of overall recovery trajectory |
| CBC with differential | Monthly | Hemoglobin normalizing (if Babesia); WBC normalizing | Tracks Babesia resolution and immune recovery |
| Herxheimer management | As needed | Temporary worsening = Borrelia die-off; manageable | Activated charcoal (away from supplements); extra hydration; temporarily reduce botanical dose if severe |
Expected Timeline
6–12 month active treatment phase, followed by indefinite maintenance. Early responders (months 1–3): fatigue improving; sleep quality improving; cognitive clarity returning. Mid-protocol (months 3–6): inflammatory markers declining; CD57 rising; joint and muscle pain decreasing 40–60%. Full protocol (months 6–12): majority achieve significant symptom resolution; 40–50% achieve near-complete remission. Note: Herxheimer reactions (symptom flare from Borrelia die-off) are expected and indicate treatment is working; they are managed, not avoided, by dose titration.
© 2026 Joshua Farriar · Christos™ Energy, Technology & Harmonic Design Consulting, LLC · All Rights Reserved · Business ID: 202511071941923